Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17326
Title: Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease.
Authors: Perin, Stephanie;Harrington, Karra D;Lim, Yen Ying;Ellis, Kathryn;Ames, David;Pietrzak, Robert H;Schembri, Adrian;Rainey-Smith, Stephanie;Salvado, Olivier;Laws, Simon M;Martins, Ralph N;Villemagne, Victor L;Rowe, Christopher C;Masters, Colin L;Maruff, Paul
Affiliation: Department of Psychology, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
United States Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, USA
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
CogState Ltd., Melbourne, Victoria, Australia
Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Nedlands, Western Australia, Australia
CSIRO Health and Biosecurity, The Australian e-Health Research Centre, Herston, Queensland, Australia
Co-operative Research Centre for Mental Health, Australia
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Mar-2018
EDate: 2018-03-15
Citation: Journal of affective disorders 2018; 229: 269-274
Abstract: Relationships between depression and Alzheimer's disease (AD) may become clearer if studied in preclinical AD where dementia is not present. The aim of this study was to evaluate prospectively, relationships between brain amyloid-β (Aβ), depressive symptoms and screen positive depression in cognitively normal (CN) older adults. Depressive symptoms were measured with the Geriatric Depression Inventory (GDS-15) in CN adults from the Australian Imaging Biomarkers and Lifestyle (AIBL) study without depression at baseline and classified as having abnormally high (Aβ+; n = 136) or low (Aβ-; n = 449) Aβ according to positron emission tomography at 18-month intervals over 72 months. Incident cases of screen positive depression were not increased in Aβ+ CN adults although small increases in overall depressive symptoms severity (d = - 0.25; 95% CI, - 0.45, - 0.05) and apathy-anxiety symptoms (d = - 0.28; 95% CI - 0.48, - 0.08) were. As the AIBL sample is an experimental sample, no individuals had severe medical illnesses or significant psychiatric disorders. Additionally, individuals who had evidence of screen-positive depression at screening were excluded from enrolment in the AIBL study. Thus, the current data can be considered only as providing a foundation for understanding relationships between Aβ and depression in preclinical AD. These results suggest that the presence of a depressive disorder or even increased depressive symptoms are themselves unlikely to be a direct consequence of increasing Aβ. New depressive disorders presenting in CN older adults could therefore be investigated for aetiologies beyond AD.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17326
DOI: 10.1016/j.jad.2017.12.101
ORCID: 0000-0003-3910-2453
PubMed URL: 29329059
Type: Journal Article
Subjects: Alzheimer's disease
Amyloid-β
Depression
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.